Skip to main content
PMC home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2004 Jan;65(1):90–96. doi: 10.1016/S0011-393X(04)90008-2

Herpes simplex pneumonia: Combination therapy with oral acyclovir and aerosolized ribavirin in an immunocompetent patient

Claudio Terzano 1,∗, Angelo Petroianni 1, Alberto Ricci 1
PMCID: PMC4052960  PMID: 24936107

Abstract

Background: Herpes simplex viruses (HSVs) are known to cause respiratory tract infections in immunocompromised hosts and, in rare instances, in immunocompetent hosts. Numerous in vitro and in vivo studies have shown that aerosolized administration of ribavirin can potently and selectively inhibit viral replication in pulmonary disease, thereby increasing the effectiveness of acyclovir in HSV.

Objective: In this case study, we reported on a 46-year-old immunocompetent woman with HSV type 1 pneumonia with bilateral pulmonary infiltrates but without mucocutaneous lesions.

Methods: The diagnosis was confirmed using cytology, viral culture, and serology. Because of the persistence of fever and dyspnea, we chose an antiviral therapy. The patient received oral acyclovir and aerosolized ribavirin to improve the antiviral effectiveness of the acyclovir and to reduce the symptoms and the time to resolution of the pulmonary disease.

Results: After 3 days of therapy, dyspnea and fever decreased and hypoxemia improved. After 2 weeks, computed tomography showed complete resolution of pulmonary abnormalities. The patient did not report any adverse effects.

Conclusions: In our case study, we demonstrated that therapy with a combination of aerosolized ribavirin and oral acyclovir may be useful to reduce the severity of viral infection, the adverse effects, and the days of hospitalization. To our knowledge, this is the first report in the literature of the synergistic effects of the combination of aerosolized ribavirin and oral acyclovir in the treatment of an immunocompetent patient with HSV pneumonia.

Keywords: herpes simplex virus, pneumonia, ribavirin, acyclovir

Full Text

The Full Text of this article is available as a PDF (438.3 KB).

References

  • 1.Ruben F.L, Nguyen M.L. Viral pneumonitis. Clin Chest Med. 1991;12:223–235. [PubMed] [Google Scholar]
  • 2.Francois-Dufresne A, Garbino J, Ricou B, Wunderli W. ARDS caused by herpes simplex virus pneumonia in a patient with Crohn's disease: A case report. Intensive Care Med. 1997;23:345–347. doi: 10.1007/s001340050339. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Cherr G.S, Meredith J.W, Chang M. Herpes simplex virus pneumonia in trauma patients. J Trauma. 2000;49:547–549. doi: 10.1097/00005373-200009000-00024. [DOI] [PubMed] [Google Scholar]
  • 4.Ramsey P.G, Fife K.H, Hackman R.C. Herpes simplex virus pneumonia: Clinical, virologic, and pathologic features in 20 patients. Ann Intern Med. 1982;97:813–820. doi: 10.7326/0003-4819-97-6-813. [DOI] [PubMed] [Google Scholar]
  • 5.Chien J.W, Johnson J.L. Viral pneumonias. Infection in the immunocompromised host. Postgrad Med. 2000;107:67–70. doi: 10.3810/pgm.2000.02.888. [DOI] [PubMed] [Google Scholar]; Chien J.W, Johnson J.L. Viral pneumonias. Infection in the immunocompromised host. Postgrad Med. 2000;107:73–74. doi: 10.3810/pgm.2000.02.888. [DOI] [PubMed] [Google Scholar]; Chien J.W, Johnson J.L. Viral pneumonias. Infection in the immunocompromised host. Postgrad Med. 2000;107:77–80. doi: 10.3810/pgm.2000.02.888. [DOI] [PubMed] [Google Scholar]
  • 6.Schuller D. LOwer respiratory tract reactivation of herpes simplex virus. Comparison of immunocompromised and immunocompetent hosts. Chest. 1994;106:S3–S7. doi: 10.1378/chest.106.1_supplement.3s. (Suppl) [DOI] [PubMed] [Google Scholar]; Schuller D. Lower respiratory tract reactivation of herpes simplex virus. Comparison of immunocompromised and immunocompetent hosts. Chest. 1994;106:S34–S35. doi: 10.1378/chest.106.1_supplement.3s. (Suppl) [DOI] [PubMed] [Google Scholar]
  • 7.Tuxen D.V, Cade J.F, McDonald M.I. Herpes simplex virus from the lower respiratory tract in adult respiratory distress syndrome. Am Rev Respir Dis. 1982;126:416–419. doi: 10.1164/arrd.1982.126.3.416. [DOI] [PubMed] [Google Scholar]
  • 8.Martinez E, de Diego A, Paradis A. Herpes simplex pneumonia in a young immunocompetent man. Eur Respir J. 1994;7:1185–1188. [PubMed] [Google Scholar]
  • 9.Aquino S.L, Dunagan D.P, Chiles C, Haponik E.F. Herpes simplex virus 1 pneumonia: Patterns on CT scans and conventional chest radiographs. J Comput Assist Tomogr. 1998;22:795–800. doi: 10.1097/00004728-199809000-00024. [DOI] [PubMed] [Google Scholar]
  • 10.Connolly M.G, Jr., Baughman R.P, Dohn M.N, Linnemann C.C., Jr. Recovery of viruses other than cytomegalovirus from bronchoalveolar lavage fluid. Chest. 1994;105:1775–1781. doi: 10.1378/chest.105.6.1775. [DOI] [PubMed] [Google Scholar]
  • 11.Miyazato A, Kishimoto H, Tamaki K. Herpes simplex virus bronchopneumonia in a non-immunocompromised individual. Intern Med. 2001;40:836–840. doi: 10.2169/internalmedicine.40.836. [DOI] [PubMed] [Google Scholar]
  • 12.Ljungman P, Ellis M.N, Hackman R.C. Acyclovir-resistant herpes simplex virus causing pneumonia after marrow transplantation. J Infect Dis. 1990;162:244–248. doi: 10.1093/infdis/162.1.244. [DOI] [PubMed] [Google Scholar]
  • 13.Neyts J, De Clercq E. The immunosuppressive agent mycophenolate mofetil markedly potentiates the activity of lobucavir [1R(1alpha,2beta,3alpha)]-9-[2,3-bis(hydroxymethyl)cyclobutyl]guanine against different herpes viruses. Transplantation. 1999;67:760–764. doi: 10.1097/00007890-199903150-00022. [DOI] [PubMed] [Google Scholar]
  • 14.Neyts J, Andrei G, De Clercq E. The antiherpesvirus activity of H2G [(R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine] is markedly enhanced by the novel immunosuppressive agent mycophenolate mofetil. Antimicrob Agents Chemother. 1998;42:3285–3289. doi: 10.1128/aac.42.12.3285. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Nicholson K.G. Antiviral therapy. Respiratory infections, genital herpes, and herpetic keratitis. Lancet. 1984;2:617–621. doi: 10.1016/S0140-6736(84)90604-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Debs R.J, Montgomery A.B, Brunette E.N. Aerosol administration of antiviral agents to treat lung infection due to murine cytomegalovirus. J Infect Dis. 1988;157:327–331. doi: 10.1093/infdis/157.2.327. [DOI] [PubMed] [Google Scholar]
  • 17.Hall C.B, McBride J.T, Walsh E.E. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study. N Engl J Med. 1983;308:1443–1447. doi: 10.1056/NEJM198306163082403. [DOI] [PubMed] [Google Scholar]
  • 18.Bray M, Martinez M, Kefauver D. Treatment of aerosolized cowpox virus in-ection in mice with aerosolizedcidofovir. Antiviral Res. 2002;54:129–142. doi: 10.1016/S0166-3542(01)00220-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Marcelletti J.F. Synergistic inhibition of herpesvirus replication by docosanol and antiviral nucleoside analogs. Antiviral Res. 2002;56:153–166. doi: 10.1016/s0166-3542(02)00105-5. [DOI] [PubMed] [Google Scholar]
  • 20.Pancheva S.N. Potentiating effect of ribavirin on the anti-herpes activity of acyclovir. Antiviral Res. 1991;16:151–161. doi: 10.1016/0166-3542(91)90021-i. [DOI] [PubMed] [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES